IPP Bureau
Touchlight & NEB launch game-changing benchtop DNA kit
By IPP Bureau - March 20, 2026
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
MedRabbits launches integrated clinic to revolutionize patient care
By IPP Bureau - March 20, 2026
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
By IPP Bureau - March 20, 2026
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
By IPP Bureau - March 20, 2026
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Roche breaks lab barriers as FDA clears mass spec tests for wider use
By IPP Bureau - March 20, 2026
The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio
SK bioscience bags fresh backing to accelerate fight against respiratory disease
By IPP Bureau - March 20, 2026
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
By IPP Bureau - March 20, 2026
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI
By IPP Bureau - March 20, 2026
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients
By IPP Bureau - March 20, 2026
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Glenmark Therapeutics USA launches fluticasone propionate nasal spray
By IPP Bureau - March 20, 2026
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
Pfizer drug candidate shows strong results in tough breast cancer study
By IPP Bureau - March 19, 2026
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
IIT Roorkee unveils cutting-edge molecular medicine facility
By IPP Bureau - March 19, 2026
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Roche unveils massive AI factory to supercharge drug development
By IPP Bureau - March 19, 2026
The facility features 2,176 high-performance GPUs across the US and Europe
Alcon walks away from LENSAR deal after regulatory roadblock
By IPP Bureau - March 19, 2026
At the center of the collapse is opposition from the Federal Trade Commission
